253 related articles for article (PubMed ID: 25612761)
1. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Akie K; Oizumi S; Ogura S; Shinagawa N; Kikuchi E; Fukumoto S; Harada M; Kinoshita I; Kojima T; Harada T; Fujita Y; Ohsaki Y; Dosaka-Akita H; Isobe H; Nishimura M;
Oncology; 2011; 81(2):84-90. PubMed ID: 21968255
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Okamoto I; Nishimura T; Miyazaki M; Yoshioka H; Kubo A; Takeda K; Ebi N; Sugawara S; Katakami N; Fukuoka M; Nakagawa K
Clin Cancer Res; 2008 Aug; 14(16):5250-4. PubMed ID: 18698044
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Yoshimura A; Chihara Y; Date K; Tamiya N; Takemura Y; Imabayashi T; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Oncologist; 2019 Apr; 24(4):459-e131. PubMed ID: 30578309
[TBL] [Abstract][Full Text] [Related]
8. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira K; Tomizawa Y; Yoshino R; Yoshii A; Matsuura M; Iwasaki Y; Koga Y; Ono A; Nishioka M; Kamide Y; Hisada T; Ishizuka T; Shirai K; Ebara T; Saitoh J; Nakano T; Sunaga N
Lung Cancer; 2013 Dec; 82(3):449-54. PubMed ID: 24099666
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
14. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
Tomonaga N; Nakamura Y; Soda H; Nagashima S; Nakano H; Kinoshita A; Fukuda M; Fukuda M; Takatani H; Soejima Y; Oka M; Kohno S;
Cancer Chemother Pharmacol; 2008 Jun; 62(1):43-9. PubMed ID: 17717667
[TBL] [Abstract][Full Text] [Related]
17. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.
Mabuchi S; Yokoi E; Shimura K; Komura N; Matsumoto Y; Sawada K; Isobe A; Tsutsui T; Kitada F; Kimura T
Int J Gynecol Cancer; 2019 Mar; 29(3):474-479. PubMed ID: 30833436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
